GSK joins EMBL’s Corporate Partnership Programme
New corporate partner supports advanced scientific training hub
GSK/Cellzome: A new corporate partner for the EMBL Advanced Training Centre
Heidelberg, 18 July 2013 – GSK/Cellzome, a subsidiary of global healthcare company GlaxoSmithKline, and the European Molecular Biology Laboratory (EMBL) have signed a corporate partnership agreement whereby GSK will support the EMBL Advanced Training Centre in Heidelberg for three years with funding for conferences and training. In return, GSK will gain access to EMBL’s state-of-the-art training facilities and may take on an advisory role to identify topics for future conferences, seminars and workshops.
The EMBL Corporate Partnership Programme connects private sector companies with the latest developments in the molecular life sciences and provides support for high-level training at the Advanced Training Centre in Heidelberg – a centre of excellence for molecular biology training in Europe. “We are very happy that GSK/Cellzome has decided to join and strengthen our impressive team of Corporate Partners. This is a win-win combination,” says Matthias Hentze, EMBL Director.
Cellzome, a drug discovery spin-off, was founded at EMBL in 2000 and acquired by GSK last year. With the diversity of science and technology ongoing at GSK, there are now many more opportunities to collaborate and leverage the history of shared interactions, as well as Cellzome’s location at EMBL headquarters in Heidelberg, Germany.
Membership of the Corporate Partnership Programme reinforces GSK’s engagement strategy with EMBL, Europe’s flagship laboratory for the life sciences: “GSK’s support of the EMBL Advanced Training Centre will increase visibility on campus and help to establish more scientific interactions with mutual benefits,” says Gitte Neubauer, Head of Cellzome.